Neural Noise

Personalized transcranial brain stimulation for depression

2 min read

  • Personalized transcranial stimulation shows benefit for depression in clinical research (UCLA Health).1
  • Targeting and dosing matter for tDCS/tACS and support a path to more reliable non-invasive neuromodulation.1 1

Weekly enrichment (2026-07-20)

  • The underlying trial (Imaging-Guided tDCS Therapy in Major Depression, JAMA Network Open 2025) was a randomized, double-blind, sham-controlled study at UCLA running December 1, 2020 to March 7, 2024; of 560 volunteers screened, 71 were eligible and randomized 1:1 (active vs. sham) with stratification by sex.2 3
  • Intervention was 20 minutes of active or sham high-definition tDCS (HD-tDCS) daily for 12 consecutive working days, with structural MRI and frameless stereotaxic neuronavigation used to personalize the left dorsolateral prefrontal cortex (DLPFC) montage to each participant.2 3
  • Eligibility required a current major depressive episode with moderate-to-severe symptoms (17-item Hamilton Depression Rating Scale [HAMD] ≥14 and <24), ages 18–65; treatment-resistant depression, bipolar disorder, and schizophrenia were excluded.2
  • The primary outcome, change in HAMD score, was −7.8 (SD 4.2) with active versus −5.6 (SD 4.4) with sham, a moderate effect size of Cohen d = −0.50 (95% CI −0.99 to −0.01; P = .04).3
  • Remission was significantly higher with active than sham HD-tDCS (39.5%, 15/38 vs. 13.3%, 4/30; P = .02), while response rates did not differ significantly (42.1% vs. 26.7%; P = .19).3 2
  • Percentage HAMD change was −44.6% (active) vs. −31.3% (sham) (P = .02), with significant group separation emerging by the mid-treatment time point (Cohen d ≈ −0.54).2
  • Treatment was well tolerated with mild-to-no adverse effects, and blinding integrity was verified.3
  • HD-tDCS differs from conventional tDCS by using smaller electrodes plus neuroimaging for a focal, personalized target; tDCS is not FDA-approved for depression and remains investigational.4
  • Context: a prior UCLA imaging RCT confirmed that HD-tDCS engages the left DLPFC target and modulates the reciprocally connected anterior cingulate cortex (d ≈ 1.06 at ACC), with stronger network modulation than a conventional montage.5

Footnotes

  1. https://news.google.com/rss/articles/CBMimwFBVV95cUxOMExXaURpcFNjVmJqbkVSbnVjVnd4cGJZTlNhQ041LWNrWEl3TGhKUVBiY2F4NkhuZnUzX2NKZk80bVc5VDlhSUNDVjQ5N3hFSjk2YW1hZC1WLWpoYzFyc1VtZjRLQVRuWk9pVmR5X1hJZmxMWDI5azdsdmFLNV9WX0g1aDh2UHkwR2thYjNlcldlUXZnOER0Y3lzTQ?oc=5 ↩ ↩2 ↩3

  2. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838763 ↩ ↩2 ↩3 ↩4 ↩5

  3. https://doi.org/10.1001/jamanetworkopen.2025.31189 ↩ ↩2 ↩3 ↩4 ↩5

  4. https://www.uclahealth.org/news/release/personalized-brain-stimulation-shows-benefit-depression ↩

  5. https://doi.org/10.1038/s41398-021-01264-3 ↩

Graph View